H.C. Wainwright raised the firm’s price target on Savara (SVRA) to $8 from $5 and keeps a Buy rating on the shares after the company announced that the Autoimmune Pulmonary Alveolar Proteinosis patient population in the U.S. is an estimated 50% greater than the company originally estimated based on an updated health claims record analysis using more recent and comprehensive records. Savara initially identified the patient population of 3,600 confirmed aPAP patients, notes the analyst, who believes that the increase in confirmed aPAP patients to 5,500 “helps to dissuade concerns regarding the initial market for Molbreevi upon anticipated launch.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara Highlights MOLBREEVI Development in New Presentation
- 3 Best Stocks to Buy Now, 8/22/2025, According to Top Analysts
- Closing Bell Movers: Nordson up 5% after Q3 earnings beat
- Savara publishes IMPALA-2 clinical trial results in NEJM
- H.C. Wainwright upgrades Savara to Buy on resubmission prospects